Loading news...
CRISPR Therapeutics' lone approved product isn't generating much revenue yet. The company has made little clinical progress elsewhere in recent years.
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $46.93, representing a -1.59% change from its previous close.
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $47.69, representing a -4.79% change from its previous close.
CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately.
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50 million aggregate principal amount of the notes.
The next big thing in artificial intelligence will very likely be located squarely between data centers and consumers. Shares of the so-called Amazon of Latin America have recently fallen out of favor, but the underlying reason is actually bullish in the long run.
Biotechnology startup CRISPR Therapeutics is issuing debt to continue developing its drug portfolio and pipeline. This new debt and/or the shareholder dilution it may lead to, however, will likely be worth it in the long run.
ZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other factors, $350 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $52.5 million aggregate principal amount of the notes.
CRISPR Therapeutics (NASDAQ: CRSP) used a fireside chat at TD Cowen's 46th Annual Healthcare Conference to outline how the company is trying to broaden its identity beyond its first commercial product, Casgevy, and build franchises in cardiovascular disease and autoimmune conditions. Chief Executive Officer and Chairman Samarth Kulkarni said 2025 was "quite the pivotal year" as
CRISPR obtained approval for Casgevy back in 2023, but the rollout has been slow. In 2025, the company incurred a loss of more than $580 million.
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
The Ark Innovation ETF is Cathie Wood's flagship fund and is heavily weighted toward innovative growth bets. The ETF recently purchased Figma, CRISPR Therapeutics, and CoreWeave.
CRISPR Therapeutics AG (NASDAQ: CRSP - Get Free Report) General Counsel James Kasinger sold 2,112 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $52.58, for a total value of $111,048.96. Following the completion of the sale, the general counsel owned 85,115
The past few years have been challenging for the biotech.
Growing revenues from Casgevy will help CRISPR Therapeutics fund the development of its pipeline therapies. The gene-editing biotech isn't profitable yet.
Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It's a great idea to select tomorrow's potential winners and hold on as their stories unfold.
CRISPR Therapeutics AG NASDAQ: CRSP stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory.
CRISPR Therapeutics is rated 'Buy' for its blockbuster CASGEVY launch, robust cash position, and high upside despite significant risks. CASGEVY's gene-editing therapy targets severe SCD and TDT, with modeled 2030 peak sales of $5.8B and orphan exclusivity until 2031. DCF-based fair value is $91.95, implying 73% upside with 57% revenue CAGR 2026-2035, but more conservative scenarios suggest CRSP might be fairly valued.
CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript